2025-09-18T07:26:36-05:00 2024-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2024-01-01 861884515 DAVOS ALZHEIMER'S COLLABORATIVE INC DAVO 7035999617 155 EAST LANCASTER AVENUE WAYNE PA 19087 ANDREW HOLZAPFEL COO 7035999617 2025-09-18 1 0 RICHARD J LOCASTRO CPA P00288314 3019519090 2024 2025-03-06 01:10:19Z GEORGE VRADENBURG 155 EAST LANCASTER AVENUE WAYNE PA 19087 9016882 0 X WWW.DAVOSALZHEIMERSCOLLABORATIVE.ORG X 2020 DC SEE PART III LINE 1. 3 2 0 2 0 0 8484685 8671988 0 300461 0 43530 0 903 8484685 9016882 1996537 1226886 0 0 0 0 0 0 414012 7013396 9167677 9009933 10394563 -525248 -1377681 14067138 13372417 1186024 1870549 12881114 11501868 X DAC IS LEADING THE LARGEST GLOBAL RESPONSE OF ITS KIND, DRIVING SCIENTIFIC DISCOVERY AND ALIGNING HEALTH SYSTEMS TO HELP PEOPLE WORLDWIDE, INCLUDING THOSE IN LOW RESOURCED ENVIRONMENTS LEFT OUT OF PREVIOUS EFFORTS TO FIGHT ALZHEIMER'S. WE ARE COMMITTED TO TRANSFORMING ALZHEIMER'S RESEARCH, PREVENTION AND CARE THROUGH PROVEN PRIVATE-PUBLIC MODELS, SUCH AS GAVI, CEPI AND THE GLOBAL FUND. 0 0 6876462 1226886 THE DAVOS ALZHEIMER'S COLLABORATIVE'S SYSTEM PREPAREDNESS PROGRAM AIMS TO STRENGTHEN HEALTHCARE SYSTEMS' ABILITY TO IDENTIFY AND ADDRESS ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) EARLY. KEY INITIATIVES INCLUDE THE EARLY DETECTION FELLOWSHIP, WHICH OFFERS TECHNICAL ASSISTANCE AND FUNDING TO HEALTHCARE ORGANIZATIONS (HCOS) TO IMPLEMENT THE EARLY DETECTION BLUEPRINT, FOSTERING COLLABORATION AMONG SELECTED SITES TO OVERCOME BARRIERS AND ENHANCE EARLY DETECTION. THE PROGRAM ALSO INCLUDES THE BRAIN HEALTH NAVIGATOR INITIATIVE, DESIGNED TO PILOT A BRAIN HEALTH NAVIGATOR MODEL IN SIX HCOS TO SUPPORT TIMELY CARE FOR PATIENTS WITH COGNITIVE DECLINE. ADDITIONALLY, THE ACCURATE DIAGNOSIS PROGRAM AIMS TO INCREASE THE USE OF NEW DIAGNOSTIC TOOLS, HELPING HEALTHCARE SYSTEMS ADOPT MORE EFFECTIVE METHODS FOR DIAGNOSING AD/ADRD. THESE EFFORTS ARE SUPPORTED BY SIGNIFICANT FUNDING AND ARE INTENDED TO IMPROVE SYSTEM PREPAREDNESS THROUGH OUTREACH, TRAINING, AND THE CREATION OF PRACTICAL TOOLKITS FOR HEALTHCARE PROVIDERS.OVERALL, OUTPUTS INCLUDE PEER-REVIEWED PUBLICATIONS, SYMPOSIUMS, POLICY COMMUNICATIONS, AND AN OPEN-ACCESS "BLUEPRINT" FOR AD/ADRD EARLY DETECTION AND SYSTEM PREPAREDNESS. DAC ALSO COLLABORATES WITH OTHER ORGANIZATIONS TO ADDRESS COMMON BARRIERS AND PROMOTE BEST PRACTICES ACROSS HEALTH SYSTEMS. 2443236 300461 THE DAVOS ALZHEIMER'S COLLABORATIVE'S GLOBAL COHORT DEVELOPMENT PROGRAM FOCUSES ON BUILDING A DIVERSE AND SUSTAINABLE NETWORK OF COHORTS TO ADVANCE ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) RESEARCH. THIS INCLUDES PARTNERSHIPS SUCH AS THE COLLABORATION WITH AGA KHAN UNIVERSITY IN NAIROBI, KENYA, WHERE COGNITIVE TESTS, SALIVA-BASED POLYGENIC RISK SCORES, AND DIGITAL COGNITIVE ASSESSMENTS ARE BEING VALIDATED IN EAST AFRICAN POPULATIONS TO CREATE A CLINICAL TRIAL-READY COHORT. IN SOUTH KOREA, DAC HAS ACQUIRED BLOOD SAMPLES FROM 300 PARTICIPANTS IN A HIGHLY CHARACTERIZED COHORT, ADVANCING THE VALIDATION OF BLOOD-BASED BIOMARKERS (BBMS) FOR GLOBAL USE. THE PROJECT ALSO INCLUDES ACCESS TO 1,000 BLOOD SAMPLES FROM A LONG-STANDING COHORT IN THE LATAM/CARIBBEAN REGION FOR AD BLOOD BIOMARKER VALIDATION, AS WELL AS A LARGE-SCALE CLINICAL TRIAL RECRUITMENT EFFORT IN THE DOMINICAN REPUBLIC, WITH OVER 14,000 PARTICIPANTS ACROSS URBAN AND RURAL SETTINGS.FURTHER EXPANDING GLOBAL RESEARCH, DAC IS DEVELOPING SCALABLE APPROACHES IN EGYPT FOR EARLY DETECTION, MONITORING, AND RISK REDUCTION OF AD, WHILE IN INDIA, THE "EYE-DEA STUDY" IS USING CATARACT SURGERY CLINICS TO ASSESS OCULAR, SPEECH, AND OLFACTORY BIOMARKERS RELATED TO COGNITIVE IMPAIRMENT. IN CHILE, DAC IS COLLECTING A WIDE RANGE OF DATA FROM A 9,000-PERSON COHORT TO GENERATE LOCAL VALIDATION DATA FOR BLOOD BIOMARKERS AND DIGITAL COGNITIVE ASSESSMENTS, PARTICULARLY FOCUSING ON THE IMPACT OF PESTICIDE USE AND EXPOSURE TO NEUROTOXINS. THESE EFFORTS ARE HELPING TO ENSURE THAT AD RESEARCH IS INCLUSIVE OF DIVERSE POPULATIONS AND ADAPTABLE TO LOCAL SETTINGS, WITH THE AIM OF IMPROVING EARLY DETECTION, DIAGNOSIS, AND TREATMENT ON A GLOBAL SCALE. THE DAVOS ALZHEIMER'S COLLABORATIVE'S GLOBAL CLINICAL TRIAL PROGRAM IS MAINTAINING A NETWORK OF MORE THAN 30 EUROPEAN SITES ORGANIZED TO ACCELERATE STUDIES AND IMPLEMENT NOVEL TRIAL DESIGNS. THIS EFFORT IS PART OF DAC'S BROADER GOAL TO BUILD INFRASTRUCTURE FOR FUTURE PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TRIALS GLOBALLY. THROUGH THE GLOBAL COHORT DEVELOPMENT PROGRAM, DAC IS WORKING TO CREATE CLINICAL TRIAL-READY POPULATIONS BY 2025, ENSURING THAT DIVERSE AND WELL-CHARACTERIZED COHORTS ARE PREPARED FOR BOTH TYPES OF INTERVENTIONS. THIS WILL EXPAND OPPORTUNITIES FOR GLOBAL CLINICAL TRIALS, ENHANCING THE ABILITY TO TEST NEW TREATMENTS AND APPROACHES IN ALZHEIMER'S DISEASE (AD) AND RELATED DEMENTIAS (ADRD) ACROSS VARIED POPULATIONS AND SETTINGS. 9319698 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 23 0 1 0 0 1 SZ 0 0 0 0 0 0 0 0 0 0 X 3 2 0 1 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 0 0 0 X X X MIKE CLEARY 6465734430 155 EAST LANCASTER AVENUE 2ND FLOOR WAYNE PA 19087 X GEORGE VRADENBURG CHAIR & PRESIDENT 20.00 2.00 X X 0 0 0 ANDREW HOLZAPFEL COO (SEE SCHEDULE O) 30.00 3.00 X X 0 0 0 FREDA LEWIS HALL TREASURER 1.00 1.00 X X 0 0 0 0 0 0 0 0 0 0 HIGH LANTERN GROUP 685 THIRD AVE 22ND FLOOR NEW YORK NY 10017 ADMIN, MARKETING, PR, AND IT 1061870 SPRINGER NATURE GROUP ONE NEW YORK PLAZA SUITE 4600 NEW YORK NY 10004 MARKETING, PROMOTION, EVENTS 758465 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1 GUSTAVE LEVY PLACE SPONSORED PRO NEW YORK NY 10029 PROGRAM RESEARCH 650000 WAKE FOREST UNIVERSITY HEALTH SERVICES MEDICAL CENTER DRIVE WINSTON SALEM NC 27157 PROGRAM RESEARCH 649994 FAEGRE DRINKER 2200 WELLS FARGO CTR 90 S 7TH ST MINNEAPOLIS MN 55402 LEGAL SERVICES 502815 11 8671988 39513 8671988 CONTRACT INCOME 900099 300461 300461 300461 43530 43530 CREDIT CARD REWARDS 900099 903 903 903 9016882 300461 0 44433 X 737016 737016 489870 489870 1061870 992489 54888 14493 501921 469126 25944 6851 196045 185612 7723 2710 5884560 5500072 304171 80317 936797 598665 60590 277542 51792 46721 2366 2705 37464 33797 1711 1956 473755 245086 202460 26209 11244 10143 514 587 SUBSCRIPTION FEES 8146 7349 372 425 MISCELLANEOUS 4083 3752 114 217 10394563 9319698 660853 414012 13720960 9007029 100000 3895504 246178 469884 14067138 13372417 1186024 1870549 1186024 1870549 X 12177430 7659407 703684 3842461 12881114 11501868 14067138 13372417 X -1377681 -1565 X 0 1 X 1 0 X 14514120 9767900 8484685 8671988 41438693 14514120 9767900 8484685 8671988 41438693 26951685 14487008 43530 43530 903 903 41483126 300461 X FORM 990, SCHEDULE A, PART II, LINE 1 THE ORGANIZATION'S EXEMPTION WAS GRANTED ON 1/12/2021 MAKING 2021 A SHORT-YEAR. THEREFORE, THE 2021 COLUMN REPRESENTS A SHORT YEAR. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 9291008 274107 19 274126 9016882 0 9016882 10671288 274107 2618 276725 10394563 0 10394563 PART XI, LINE 2D - OTHER ADJUSTMENTS: RELATED ORG. REVENUE INCLUDED IN THE CONSOLIDATED FINANCIAL 19. STATEMENTS, BUT EXCLUDED FROM PART VIII OF THE FORM 990. PART XII, LINE 2D - OTHER ADJUSTMENTS: RELATED ORG. EXPENSES INCLUDED IN THE CONSOLIDATED 2,618. FINANCIAL STATEMENTS, BUT EXCLUDED FROM PART IX OF THE FORM 990. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 102400 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 365500 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 17970 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THE REGION 4000 EAST ASIA AND THE PACIFIC 0 3 PROGRAM SERVICES SHIPPING EXPENSES & SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 26886 EUROPE (INCLUDING ICELAND & GREENLAND) 0 23 PROGRAM SERVICES RESEARCH SERVICES, CONFERENCE, LEGAL SERVICES, TRAVEL, PROFESSIONAL FEES, SPONSORSHIP 492020 MIDDLE EAST AND NORTH AFRICA 0 3 PROGRAM SERVICES RESEARCH SITE AND RESEARCH SERVICES 189685 NORTH AMERICA 0 10 PROGRAM SERVICES RESEARCH SITE, PROGRAM SERVICES AND TRAVEL 492681 SOUTH AMERICA 0 2 PROGRAM SERVICES RESEARCH SITE, SPONSORSHIP AND PROGRAM SERVICES 371109 SOUTH ASIA 0 4 PROGRAM SERVICES RESEARCH SITE, RESEARCH SERVICES AND TRAVEL 128706 SUB-SAHARAN AFRICA 0 10 PROGRAM SERVICES RESEARCH SITE, PROGRAM SERVICES AND RESEARCH SERVICES 348414 0 39 0 16 0 55 1691142 848229 2539371 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 12400 WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 90000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 148500 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 125000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SPONSORSHIP FOR CONFERENCE 25000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SPONSORSHIP 12000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SPONSORSHIP FOR CONFERENCE 20000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SPONSORSHIP FOR CONFERENCE 35000 WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE 17970 WIRE TRANSFER 0 9 0 1 0 0 0 0 0 PART I, LINE 2: GRANTEE PROVIDES WRITTEN REPORTS AT DESIGNATED TIMES OR MILESTONES. DAC PROVIDES A SAMPLE REPORT FOR GRANTEES TO USE UNLESS OTHERWISE SPECIFIED. GRANTEES ARE REQUIRED TO PARTICIPATE IN DAC FORUMS AND PROGRAMS. GRANTEE PROVIDES DAC WITH A ROYALTY-FREE LICENSE OR OTHER PERMISSION/AUTHORIZATION NECESSARY FOR DAC TO PUBLISH INSIGHTS AND KEY FINDINGS RESULTING FROM THE PROJECT, AS SHARED WITH DAC AND THE FORUMS AND PROGRAMS (ALL IN AGGREGATE OR SUMMARY FORM). GRANTEE WILL MAINTAIN COMPLETE AND ACCURATE RECORDS OF RECEIPTS AND EXPENDITURES CHARGED AGAINST THE GRANT THAT ARE SUFFICIENTLY DETAILED TO IDENTIFY THE USE OF FUNDS IN COMPLIANCE WITH THE GRANT AGREEMENT. DAC REPRESENTATIVES REVIEW THESE RECORDS AND THE RECORDS ARE TO BE MAINTAINED FOR A MINIMUM OF 3 YEARS AFTER THE COMPLETION OF THE GRANT. 1 COMMONSPIRIT HEALTH 198 INVERNESS DRIVE WEST ENGLEWOOD CO 80112 470617373 82500 0 FELLOWSHIP WASHINGTON UNIVERSITY IN ST LOUIS 7425 FORSYTH BLVD MSC 1299-414-355 ST LOUIS MO 63105 430653611 36432 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE ADVOCATE AURORA HEALTH 3075 HIGHLAND PARKWAY DOWNERS GROVE IL 60515 362167779 501(C)(3) 124911 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE BARROW NEUROLOGICAL FOUNDATION 2910 NORTH 3RD AVE PHOENIX AZ 85013 860174371 501(C)(3) 25000 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE EMORY UNIVERSITY 1599 CLIFTON ROAD NE - 4TH FLOOR ATLANTA GA 30322 580566256 501(C)(3) 82500 0 FELLOWSHIP FAMILY HEALTH CENTERS OF SOUTHERN INDIANA 1319 DUNCAN AVE JEFFERSONVILLE IN 47130 351842342 501(C)(3) 82500 0 FELLOWSHIP MEDICAL UNIVERSITY OF SOUTH CAROLINA (MUSC) 1 SOUTH PARK CIRCLE BUILDING 1 SUITE 402 CHARLESTON SC 29407 576000722 501(C)(3) 82500 0 FELLOWSHIP SCAN HEALTH PLAN 3800 KILROY AIRPORT WAY SUITE 100 LONG BEACH CA 90806 953858259 501(C)(3) 82500 0 FELLOWSHIP UMASS MEMORIAL HEALTH - HARRINGTON 365 PLANTATION STREET SUITE 301 WORCESTER MA 01605 043358566 501(C)(3) 82500 0 FELLOWSHIP UNIVERSITY OF PENNSYLVANIA TRUSTEES OF 3451 WALNUT STREET5TH FLOOR FRANKLIN BUILDING PHILADELPHIA PA 191046205 231352685 501(C)(3) 82500 0 FELLOWSHIP VIRTUA HEALTH FOUNDATION (VHF) 303 LIPPINCOTT DR 4TH FLOOR MARLTON NJ 08053 043722352 82500 0 FELLOWSHIP UNIVERSITY OF WASHINGTON 4300 ROOSEVELT WAY NE BOX 354965 SEATTLE WA 98105 916001537 STATE GOVERNMENT 220677 0 SCIENTIFIC RESEARCH FOR ALZHEIMER'S DISEASE GLOBAL ALZHEIMER'S PLATFORM FOUNDATION 1771 POST RD EAST 250 WESTPORT CT 06880 473290570 501(C)(3) 20191 0 2024 SPONSORSHIP OF AAIC RECEPTION 10 3 PART I, LINE 2: GRANTEE PROVIDES WRITTEN REPORTS AT DESIGNATED TIMES OR MILESTONES. DAC PROVIDES A SAMPLE REPORT FOR GRANTEES TO USE UNLESS OTHERWISE SPECIFIED. GRANTEES ARE REQUIRED TO PARTICIPATE IN DAC FORUMS AND PROGRAMS. GRANTEE PROVIDES DAC WITH A ROYALTY-FREE LICENSE OR OTHER PERMISSION/AUTHORIZATION NECESSARY FOR DAC TO PUBLISH INSIGHTS AND KEY FINDINGS RESULTING FROM THE PROJECT, AS SHARED WITH DAC AND THE FORUMS AND PROGRAMS (ALL IN AGGREGATE OR SUMMARY FORM). GRANTEE WILL MAINTAIN COMPLETE AND ACCURATE RECORDS OF RECEIPTS AND EXPENDITURES CHARGED AGAINST THE GRANT THAT ARE SUFFICIENTLY DETAILED TO IDENTIFY THE USE OF FUNDS IN COMPLIANCE WITH THE GRANT AGREEMENT. DAC REPRESENTATIVES AUDIT THESE RECORDS AND THE RECORDS ARE TO BE MAINTAINED FOR A MINIMUM OF 3 YEARS AFTER THE COMPLETION OF THE GRANT. X 2 39513 FMV 0 0 0 PART I, COLUMN (B): THE NUMBER IN COLUMN (B) REPRESENTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART VI, SECTION A, LINE 3 THE DAVOS ALZHEIMERS COLLABORATIVE, INC. (DAC) RETAINED AN INDEPENDENT CONTRACTOR, HIGH LANTERN GROUP, LLC (HLG), TO PROVIDE A SUITE OF MANAGEMENT SERVICES AND ADMINISTRATIVE SUPPORT, AS WELL AS THOSE DUTIES CUSTOMARILY PERFORMED BY AN ORG. CHAIR/PRESIDENT AND COO. DAC COMPENSATED HLG $1,061,870 FOR THOSE SERVICES. THE DUTIES OF THE CHAIR/PRESIDENT AND COO WERE PROVIDED TO DAC BY GEORGE VRADENBURG AND ANDREW HOLZAPFEL, RESPECTIVELY. OF THE $1,061,870 COMPENSATION PAID TO HLG BY DAC, $70,000 IS RELATED TO THE SERVICES PROVIDED BY ANDREW HOLZAPFEL. GEORGE VRADENBURG DOES NOT RECEIVE ANY SALARY OR PAYMENT. FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION HAS NO COMMITTEE WITH THE AUTHORITY TO ACT ON BEHALF OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTANTS. THE 990 WAS THEN REVIEWED WITH DAC'S COO AND CHAIR/PRESIDENT WITH THE AUDITORS. IT WAS THEN SHARED WITH THE BOARD AND FINALIZED UPON APPROVAL. FORM 990, PART VI, SECTION B, LINE 12C ALL OFFICERS, DIRECTORS OR TRUSTEES AND KEY EMPLOYEES(CONTRACTORS) ARE REQUIRED TO SIGN THE CONFLICT OF INTEREST POLICY AT THE FIRST BOARD MEETING OF THE YEAR AND UPON CONTRACTING OR DATE OF HIRE. IF A CONFLICT OF INTEREST IS FOUND, THE MATTER IS PRESENTED TO THE BOARD. THE APPLICABLE INTERESTED PERSON MAKES A PRESENTATION AT THE BOARD MEETING, BUT AFTER THE PRESENTATION, HE OR SHE REFRAINS FROM VOTING OR OTHERWISE ATTEMPTING TO EXERT ANY INFLUENCE ON WHETHER THE CORPORATION SHOULD PARTICIPATE OR NOT PARTICIPATE IN SUCH TRANSACTION AND LEAVES THE MEETING DURING THE DISCUSSION OF, AND VOTE ON, THE TRANSACTION OR ARRANGEMENT INVOLVING THE POSSIBLE CONFLICT OF INTEREST. AFTER EXERCISING DUE DILIGENCE, THE BOARD DETERMINES WHETHER THE CORPORATION CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY POSSIBLE UNDER CIRCUMSTANCES NOT PRODUCING A CONFLICT OF INTEREST, THE BOARD DETERMINES BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN THE CORPORATION'S BEST INTEREST, WHETHER IT IS FAIR, REASONABLE, AND THE RESULT OF ARM'S-LENGTH BARGAINING, AND WHETHER IT REFLECTS REASONABLE INVESTMENT CRITERIA OR PAYMENTS FOR GOODS AND SERVICES, FURTHERS THE CORPORATION'S PURPOSES AND DOES NOT RESULT IN PRIVATE INUREMENT, IMPERMISSIBLE PRIVATE BENEFIT OR AN EXCESS BENEFIT TRANSACTION. IN CONFORMITY WITH THE ABOVE DETERMINATION, THE BOARD OR COMMITTEE MAKES ITS DECISION IN WRITING AND ON THE RECORD AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G PROJECT MANAGEMENT: PROGRAM SERVICE EXPENSES 1,299,994. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,299,994. MARKETING CONSULTANT: PROGRAM SERVICE EXPENSES 758,465. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 758,465. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 44,119. MANAGEMENT AND GENERAL EXPENSES 116,279. FUNDRAISING EXPENSES 30,704. TOTAL EXPENSES 191,102. RESEARCH FEES: PROGRAM SERVICE EXPENSES 3,397,494. MANAGEMENT AND GENERAL EXPENSES 187,892. FUNDRAISING EXPENSES 49,613. TOTAL EXPENSES 3,634,999. FORM 990, PART XI, LINE 9: CURRENCY EXCHANGE LOSS -1,565. DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE) COURS DE RIVE 13 C/O PESTALOZZI AV GENEVE SZ 1204 PROMOTE HEALTH BY DEVELOPING RESEARCH ON BRAIN HEALTH.. SZ N/A N/A DAC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 DAVOS ALZHEIMER'S COLLABORATIVE (GENEVE) Q 2542 ACTUAL COST